Search | Clinical Trials Finder

Conditions: Submental Fat
Interventions: RZL-012, Placebo; Drug
Lead sponsor: Raziel Therapeutics Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 151 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Meibomian Gland Dysfunction (MGD)
Interventions: Vevye(Cyclosporine 0.1% Ophthalmic Solution); Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Healthy Volunteers
Interventions: [14C]-BGB-16673; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Actinic Keratosis
Interventions: Aminolevulinic Acid, Topical Solution Vehicle, BLU-U, Cryotherapy; Drug · Device · Procedure
Lead sponsor: DUSA Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 8
States / cities: San Diego, California • Arlington Heights, Illinois • Carmel, Indiana + 4 more

Conditions: Frontal Fibrosing Alopecia
Interventions: Delgocitinib cream, Delgocitinib cream vehicle; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Burlington, Massachusetts

Conditions: Generalized Epidermolysis Bullosa Simplex
Interventions: AC-203, Vehicle; Drug
Lead sponsor: TWi Biotechnology, Inc.; Industry
Eligibility: 6 Months and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Rancho Santa Margarita, California • Stanford, California • Aurora, Colorado + 4 more

Conditions: Benign Prostatic Hyperplasia
Interventions: PRX302, Placebo; Drug · Other
Lead sponsor: Sophiris Bio Corp; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 479 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 45
States / cities: Huntsville, Alabama • Anchorage, Alaska • Laguna Hills, California + 40 more

Conditions: Healthy
Interventions: diacerein 1% ointment; Drug
Lead sponsor: Castle Creek Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Acne Vulgaris
Interventions: Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light, Vehicle Foam without irradiation, Vehicle Foam with UVA and UVB irradiation, Vehicle Foam with UVA and UVB and visible light irradiation, No Treatment without irradiation, No Treatment with UVA and UVB irradiation, No Treatment with UVA and UVB and visible light irradiation; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Stretch Marks, Striae Distensae, Cosmetic Appearance of Stretch Marks
Interventions: Placebo Vehicle Cream, Centella Asiatica Cream; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Surgery
Interventions: Chlorhexidine Gluconate, Vehicle, DynaHex-2; Drug · Other
Lead sponsor: Medline Industries; Industry
Eligibility: 16 Years and older
Enrollment: 347 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Sterling, Virginia

Conditions: Healthy
Interventions: Diacerein 1% ointment; Drug
Lead sponsor: Castle Creek Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Heart Failure With Preserved Ejection Fraction
Interventions: JK07, Matching Placebo; Drug
Lead sponsor: Salubris Biotherapeutics Inc; Industry
Eligibility: 18 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 7
States / cities: Stanford, California • Boston, Massachusetts • Rochester, Minnesota + 4 more

Conditions: Dry Eye Disease
Interventions: Topical spironolactone ophthalmic solution, 0.005 mg/cc, Placebo; Drug
Lead sponsor: Richard W Yee, MD; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Bellaire, Texas

Conditions: Knee Osteoarthritis
Interventions: PTP-01, Placebo control / saline vehicle; Biological · Other
Lead sponsor: Doron Therapeutics Inc.; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • La Mesa, California • West Hills, California + 5 more

Conditions: Dercum's Disease Lipomas
Interventions: RZL-012, Vehicle; Drug
Lead sponsor: Raziel Therapeutics Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Inflammation, Pain, Cataract
Interventions: XG-102, Placebo; Drug
Lead sponsor: Xigen SA; Industry
Eligibility: 18 Years and older
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Plaque Psoriasis
Interventions: Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%, Placebo; Drug
Lead sponsor: Sun Pharmaceutical Industries, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Acute Adenoviral Conjunctivitis
Interventions: FST-100, FST-100 (Component #1), FST-100 Vehicle; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Fecal Incontinence
Interventions: Iltamiocel, Placebo; Biological · Other
Lead sponsor: Cook MyoSite; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 25
States / cities: La Jolla, California • Orange, California • San Francisco, California + 21 more

Conditions: Anemia, Iron-Deficiency
Interventions: CSJ137, Placebo; Biological · Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 5
States / cities: San Diego, California • Lakewood, Colorado • Orlando, Florida + 2 more

Conditions: Degenerative Disc Disease
Interventions: Single Dose MPCs Injection, Single injection of saline solution, Single injection of hyaluronic acid; Biological · Procedure
Lead sponsor: Mesoblast, Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 13
States / cities: Scottsdale, Arizona • Sacramento, California • Santa Monica, California + 10 more

Conditions: Open-angle Glaucoma (OAG), Ocular Hypertension (OHT), Glaucoma
Interventions: QLS-111, 0.015%, QLS-111, 0.030%, QLS-111, 0.075%, QLS-111 vehicle ophthalmic solution; Drug
Lead sponsor: Qlaris Bio, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Allergic Conjunctivitis
Interventions: EM-100, Zaditor®, Vehicle; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

Efficacy and Safety of RZL-012 on Submental Fat Reduction

Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction

A Study of How [14C]-BGB-16673 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Participants

Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy

A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia

An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)

Randomized, Double-Blind, Vehicle-Controlled, Multicenter Safety and Efficacy Study of Intraprostatic PRX302 for LUTS BPH

A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

Topical Centella Asiatica and the Cosmetic Appearance of Stretch Marks

Preoperative Chlorhexidine Gluconate (CHG) Cloth on Healthy Subjects

A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers

Single-Ascending Dose Study of JK07 in Subjects With HFpEF

The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease

A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients

RZL-012 for Dercum's Disease Lipomas

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

FST-100 in the Treatment of Acute Adenoviral Conjunctivitis

Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric Injury

A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients

Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

A Single-Center Evaluation of the Relative Efficacy of EM-100 Compared to Zaditor® (Ketotifen Fumarate Ophthalmic Solution 0.035%) and Vehicle